Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference ( p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.
【저자키워드】 Lebanon, clinical trial, pandemic, therapy, 【초록키워드】 Randomized controlled trial, Ivermectin, Treatment, SARS-CoV-2, Efficacy, SARS-CoV2, Trial, Clinical symptoms, Hospitalization, body weight, virus, Symptoms, Randomized, Viral, Asymptomatic, Viral load, Patient, Ct-value, single dose, Ct values, Hospital admissions, regimen, preventive treatment, significant difference, control group, two groups, no significant difference, both groups, subject, ivermectin group, FDA-approved drug, asymptomatic subjects, clinical benefits, Ct-values, experimental group, individual, viral loads, clinical benefit, positive, resulting, tested, addition, required, conducted, reduced, appear, determine, subjects, increase in, producing, two group, asymptomatic subject, in both group, 【제목키워드】 SARS-CoV-2, clinical, Effect,